Glycan recognition by human blood mononuclear cells with an emphasis on dendritic cells

• Published in: Glycoconjugate journal Vol. 35; no. 2; pp. 191 - 203
• Main Authors: Rapoport, Eugenia M., Khaidukov, Sergey V., Gaponov, Andrey M., Pazynina, Galina V., Tsygankova, Svetlana V., Ryzhov, Ivan M., Belyanchikov, Ivan M., Milona, Panagiota, Bovin, Nicolai V., McCullough, Kenneth C.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-04-2018; Springer Nature B.V
• Subjects: Adaptive immunity; Antigen presentation; Antigens; Biochemistry; Biomedical and Life Sciences; Blood; CD14 antigen; CD16 antigen; CD83 antigen; DC-SIGN protein; Dendritic cells; Galactose; Immune response; Lectins; Leukocytes (mononuclear); Life Sciences; Lymphocytes; Lymphocytes T; Macrophages; Mannose; Monocytes; Original Article; Pathology; Polysaccharides; T cell receptors; Vaccine development; Vaccines; Monocytes; MGL; MMR; Dendritic cells; DC-SIGN; Lectins; Glycans
• ISSN: 0282-0080; 1573-4986
• DOI: 10.1007/s10719-017-9811-6

Dendritic cells (DCs) play crucial roles in innate and adaptive immune response, for which reason targeting antigen to these cells is an important strategy for improvement of vaccine development. To this end, we explored recognition of DCs lectins by glycans. For selection of the glycan “vector”, a library of 229 fluorescent glycoprobes was employed to assess interaction with the CD14
low/-
CD16
+
CD83
+
blood mononuclear cell population containing the DCs known for their importance in antigen presentation to T-lymphocytes. It was found that: 1) the glycan-binding profiles of this CD14
low/-
CD16
+
CD83
+
subpopulation were similar but not identical to DCs of monocyte origin (moDCs); 2) the highest percentage of probe-positive cells in this CD14
low/-
CD16
+
CD83
+
subpopulation was observed for GalNAcα1-2Galβ (A
di
), (Neu5Acα)
3
and three mannose-reach glycans; 3) subpopulation of CD14
low/-
CD16
+
cells preferentially bound 4’-O-Su-LacdiNAc. Considering the published data on specificity of DCs binding, the glycans showing particular selectivity for the CD14
low/-
CD16
+
CD83
+
cells are likely interacting with macrophage galactose binding lectin (MGL), siglec-7 and dectin-2. In contrast, DC-SIGN is not apparently involved, even in case of mannose-rich glycans. Taking into consideration potential
in vivo
competition between glycan “vectors” and glycans within glycocalyx, attempting to target vaccine to DCs glycan-binding receptors should focus on A
di
and (Neu5Acα)
3
as the most promising vectors.